NEW YORK (GenomeWeb News) - Affymetrix will market Asuragen’s in vitro transcription reagent kits for use with its diagnostic microarray platform, the companies said today.  
 
Under the terms of the agreement, Asuragen will develop and manufacture IVT reagent kits configured for use with Affy’s GeneChip System 3000Dx, a diagnostic microarray platform that has gained 510(k) clearance from the US Food and Drug Administration and the CE mark from the European Union.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.

Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.

In Science this week: in vitro generation of human reproductive cells, and more.

Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.